AU2005297303B2 - Novel diagnostic kit for malignant melanoma - Google Patents

Novel diagnostic kit for malignant melanoma Download PDF

Info

Publication number
AU2005297303B2
AU2005297303B2 AU2005297303A AU2005297303A AU2005297303B2 AU 2005297303 B2 AU2005297303 B2 AU 2005297303B2 AU 2005297303 A AU2005297303 A AU 2005297303A AU 2005297303 A AU2005297303 A AU 2005297303A AU 2005297303 B2 AU2005297303 B2 AU 2005297303B2
Authority
AU
Australia
Prior art keywords
sparc
melanoma
gpc3
protein
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005297303A
Other languages
English (en)
Other versions
AU2005297303A1 (en
Inventor
Yoshiaki Ikuta
Tetsuya Nakatsura
Yasuharu Nishimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LSIP LLC
Original Assignee
LSIP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LSIP LLC filed Critical LSIP LLC
Publication of AU2005297303A1 publication Critical patent/AU2005297303A1/en
Application granted granted Critical
Publication of AU2005297303B2 publication Critical patent/AU2005297303B2/en
Assigned to LSIP, LLC reassignment LSIP, LLC Request for Assignment Assignors: KUMAMOTO UNIVERSITY
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2005297303A 2004-10-19 2005-08-09 Novel diagnostic kit for malignant melanoma Ceased AU2005297303B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004-303688 2004-10-19
JP2004303688 2004-10-19
PCT/JP2005/014567 WO2006043362A1 (ja) 2004-10-19 2005-08-09 悪性黒色腫（メラノーマ）の新規な診断キット

Publications (2)

Publication Number Publication Date
AU2005297303A1 AU2005297303A1 (en) 2006-04-27
AU2005297303B2 true AU2005297303B2 (en) 2011-11-10

Family

ID=36202786

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005297303A Ceased AU2005297303B2 (en) 2004-10-19 2005-08-09 Novel diagnostic kit for malignant melanoma

Country Status (6)

Country Link
US (1) US8017345B2 (https=)
EP (1) EP1813943B1 (https=)
JP (1) JP4834839B2 (https=)
AU (1) AU2005297303B2 (https=)
DE (1) DE602005016831D1 (https=)
WO (1) WO2006043362A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2373055T3 (es) 2005-08-09 2012-01-31 Oncotherapy Science, Inc. Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
AU2007259667B2 (en) * 2006-06-16 2012-06-14 Oncotherapy Science, Inc. SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same
CN102089444A (zh) 2008-05-14 2011-06-08 德玛泰克国际公司 利用核酸分析方法来诊断黑素瘤和太阳能雀斑
BRPI0923155A2 (pt) * 2008-12-05 2018-10-23 Abraxis Bioscience Llc scfcs de ligação a sparc
AU2010295324B2 (en) * 2009-09-18 2015-04-30 Abraxis Bioscience, Llc Use of the SPARC microenvironment signature in the treatment of cancer
WO2011137114A1 (en) * 2010-04-26 2011-11-03 Abraxis Bioscience, Llc Sparc binding antibodies and uses thereof
MX2012013874A (es) 2010-06-03 2013-01-24 Abraxis Bioscience Llc Uso de la signatura en el microentorno de sparc en el tratamiento de cancer.
US20130281376A1 (en) * 2010-10-08 2013-10-24 Abraxis Bioscience, Llc Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer
EP2863224A4 (en) * 2012-06-18 2016-05-04 Nat Cancer Ct KIT FOR DIAGNOSIS MALIGNER MELANOME
US20140314697A1 (en) * 2013-04-18 2014-10-23 Corum Inc. Method for Inhibiting Inflammation and Reducing Melanophilin Expression with Glycine Derivatives And the Composition Thereof
US20150005184A1 (en) * 2013-06-28 2015-01-01 Dermtech International Diagnosis of melanoma by nucleic acid analysis
CA3090785A1 (en) 2018-02-14 2019-08-22 John Daniel Dobak Iii Novel gene classifiers and uses thereof in non-melanoma skin cancers
JP2022524641A (ja) 2019-03-26 2022-05-09 ダームテック，インク． 皮膚癌における新規な遺伝子分類子とその使用
US12576166B2 (en) 2020-07-27 2026-03-17 Board Of Regents, The University Of Texas System Contrast agents for detection of enzyme activities based on melanin synthesis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064626A2 (en) * 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
AU2003281325A1 (en) * 2002-07-02 2004-01-23 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
WO2004020624A1 (ja) * 2002-08-30 2004-03-11 Kumamoto Technology & Industry Foundation 癌抗原及びその利用
AU2004260083B2 (en) * 2003-07-17 2011-04-07 Pacific Edge Limited Markers for detection of gastric cancer
EP1684076B1 (en) * 2003-10-29 2008-12-31 Kumamoto Technology & Industry Foundation Diagnostic method for malignant melanoma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEDDA, F. et al. The Journal of Investigative Dermatology. 1997, vol. 108(2), pages 210-214 *
NAKATSURA, T. et al. Clinical Cancer Research. vol. 10, pages 6612-6621 *

Also Published As

Publication number Publication date
JPWO2006043362A1 (ja) 2008-05-22
EP1813943B1 (en) 2009-09-23
DE602005016831D1 (https=) 2009-11-05
JP4834839B2 (ja) 2011-12-14
AU2005297303A1 (en) 2006-04-27
US20090111095A1 (en) 2009-04-30
US8017345B2 (en) 2011-09-13
EP1813943A1 (en) 2007-08-01
EP1813943A4 (en) 2007-12-12
WO2006043362A1 (ja) 2006-04-27

Similar Documents

Publication Publication Date Title
JP5006802B2 (ja) 上皮由来の癌診断および予後診断のためのバイオマーカーとしてのＣｙｒ６１
JP4594575B2 (ja) がんのマーカーとして使用されるアネキシン類及び自己抗体
Jou et al. Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages
AU2005297303B2 (en) Novel diagnostic kit for malignant melanoma
CN101421622A (zh) 作为癌症生物标志物的游离ngal
JP2739110B2 (ja) ヒト乳ガンの分析
US8642347B2 (en) Urinary CA125 peptides as biomarkers of ovarian cancer
AU2004283614B2 (en) Diagnostic agent for malignant melanoma
Hamrita et al. An elongation factor-like protein (EF-Tu) elicits a humoral response in infiltrating ductal breast carcinomas: an immunoproteomics investigation
KR101486548B1 (ko) 나이관련 황반변성 진단용 마커 및 이를 이용한 나이 관련 황반 변성 진단 방법
KR101311717B1 (ko) 대장암 진단용 단백질 마커 멜라노트랜스페린 및 이에 대한 항체를 포함하는 대장암 진단 키트
KR102141546B1 (ko) 난청 예후 예측방법 및 이를 이용한 키트
KR100896328B1 (ko) 대사성 질환의 진단 마커로 유용한 프로그레뉼린
KR20120021518A (ko) 간암 진단용 조성물 및 진단방법
US20130040325A1 (en) Enzyme Linked Immunosorbent Assay (ELISA) Method and Kit for Detecting Soluble Programmed Cell Death Protein 5 (PDCD5)
JP7565046B2 (ja) がんの骨転移を検出する方法及び検出試薬
KR101431063B1 (ko) 유방암 진단용 단백질 마커 아포리포단백질 ｃ-1, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트
KR100991289B1 (ko) 유방암 진단용 ａ２―ＨＳ 당단백질에 대한 자가항체마커및 진단키트
AU2001247317A1 (en) A lysosomal pepstatin-insensitive proteinase as a novel biomarker for detecting and diagnosing breast cancer
JP2010139293A (ja) 早期癌腫瘍マーカー
JPWO2001020333A1 (ja) 早期癌腫瘍マーカー

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LSIP, LLC

Free format text: FORMER APPLICANT(S): KUMAMOTO UNIVERSITY

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired